Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01554800 | Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease | PHASE1 | COMPLETED | 16 | — | — | Mar 1, 2012 | Sep 1, 2012 | Mar 14, 2019 | 1 | United States |
Safety and tolerability of a single dose of ACP-501 as determined by adverse event reporting, clinical laboratory results, vital signs, physical examination, and electrocardiograms (ECGs).
| Arm | Type | Description |
|---|---|---|
| ACP-501 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ACP-501 | DRUG | A single dose infusion |
Inclusion Criteria: * A history of stable documented CAD * Currently non-smoking males and females ages 30 to 85 years inclusive. o Female subjects of child-bearing potential (neither pregnant nor breast-feeding) must be using adequate birth control during study conduct. * Chronic concomitant me...